These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

643 related items for PubMed ID: 29890208

  • 1. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
    Shi Q, Shen LY, Dong B, Fu H, Kang XZ, Yang YB, Dai L, Yan WP, Xiong HC, Liang Z, Chen KN.
    Cancer Lett; 2018 Sep 28; 432():56-68. PubMed ID: 29890208
    [Abstract] [Full Text] [Related]

  • 2. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.
    Li CC, Yang JC, Lu MC, Lee CL, Peng CY, Hsu WY, Dai YH, Chang FR, Zhang DY, Wu WJ, Wu YC.
    Oncotarget; 2016 Jan 12; 7(2):1947-59. PubMed ID: 26657501
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
    Nam AR, Jin MH, Park JE, Bang JH, Oh DY, Bang YJ.
    Cancer Res Treat; 2019 Jul 12; 51(3):1167-1179. PubMed ID: 30514066
    [Abstract] [Full Text] [Related]

  • 4. eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma.
    Liu T, Li R, Zhao H, Deng J, Long Y, Shuai MT, Li Q, Gu H, Chen YQ, Leng AM.
    Oncotarget; 2016 Oct 11; 7(41):66851-66864. PubMed ID: 27588477
    [Abstract] [Full Text] [Related]

  • 5. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation.
    Gomes LR, Rocha CRR, Martins DJ, Fiore APZP, Kinker GS, Bruni-Cardoso A, Menck CFM.
    Cell Death Dis; 2019 Jun 12; 10(6):459. PubMed ID: 31189884
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ.
    Cancer Lett; 2016 Dec 01; 383(1):41-52. PubMed ID: 27693461
    [Abstract] [Full Text] [Related]

  • 7. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F, George J, Schmitt A, Beleggia F, Rehkämper T, Hermann S, Walter V, Weber JP, Thomas RK, Wittersheim M, Büttner R, Persigehl T, Reinhardt HC.
    Sci Rep; 2017 Nov 14; 7(1):15511. PubMed ID: 29138515
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.
    Combès E, Andrade AF, Tosi D, Michaud HA, Coquel F, Garambois V, Desigaud D, Jarlier M, Coquelle A, Pasero P, Bonnefoy N, Moreaux J, Martineau P, Del Rio M, Beijersbergen RL, Vezzio-Vie N, Gongora C.
    Cancer Res; 2019 Jun 01; 79(11):2933-2946. PubMed ID: 30987998
    [Abstract] [Full Text] [Related]

  • 9. Long non-coding RNA LINC00337 induces autophagy and chemoresistance to cisplatin in esophageal squamous cell carcinoma cells via upregulation of TPX2 by recruiting E2F4.
    Yang C, Shen S, Zheng X, Ye K, Ge H, Sun Y, Lu Y.
    FASEB J; 2020 May 01; 34(5):6055-6069. PubMed ID: 32239565
    [Abstract] [Full Text] [Related]

  • 10. ATR inhibition sensitizes HPV- and HPV+ head and neck squamous cell carcinoma to cisplatin.
    Leonard BC, Lee ED, Bhola NE, Li H, Sogaard KK, Bakkenist CJ, Grandis JR, Johnson DE.
    Oral Oncol; 2019 Aug 01; 95():35-42. PubMed ID: 31345392
    [Abstract] [Full Text] [Related]

  • 11. Enhanced cancer stem cell properties of a mitotically quiescent subpopulation of p75NTR-positive cells in esophageal squamous cell carcinoma.
    Kojima H, Okumura T, Yamaguchi T, Miwa T, Shimada Y, Nagata T.
    Int J Oncol; 2017 Jul 01; 51(1):49-62. PubMed ID: 28534989
    [Abstract] [Full Text] [Related]

  • 12. Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin.
    Wang F, Ding X, Wang T, Shan Z, Wang J, Wu S, Chi Y, Zhang Y, Lv Z, Wang L, Fan Q.
    PLoS One; 2017 Jul 01; 12(4):e0174276. PubMed ID: 28406985
    [Abstract] [Full Text] [Related]

  • 13. Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis.
    Yu X, Li W, Xia Z, Xie L, Ma X, Liang Q, Liu L, Wang J, Zhou X, Yang Y, Liu H.
    BMC Cancer; 2017 Jun 28; 17(1):449. PubMed ID: 28659182
    [Abstract] [Full Text] [Related]

  • 14. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
    Song N, Jing W, Li C, Bai M, Cheng Y, Li H, Hou K, Li Y, Wang K, Li Z, Liu Y, Qu X, Che X.
    Cell Cycle; 2018 Jun 28; 17(5):595-604. PubMed ID: 29157079
    [Abstract] [Full Text] [Related]

  • 15. Methylation of NRN1 is a novel synthetic lethal marker of PI3K-Akt-mTOR and ATR inhibitors in esophageal cancer.
    Du W, Gao A, Herman JG, Wang L, Zhang L, Jiao S, Guo M.
    Cancer Sci; 2021 Jul 28; 112(7):2870-2883. PubMed ID: 33931924
    [Abstract] [Full Text] [Related]

  • 16. In Vivo and In Vitro Effects of ATM/ATR Signaling Pathway on Proliferation, Apoptosis, and Radiosensitivity of Nasopharyngeal Carcinoma Cells.
    Wang M, Liu G, Shan GP, Wang BB.
    Cancer Biother Radiopharm; 2017 Aug 28; 32(6):193-203. PubMed ID: 28820634
    [Abstract] [Full Text] [Related]

  • 17. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
    Vendetti FP, Lau A, Schamus S, Conrads TP, O'Connor MJ, Bakkenist CJ.
    Oncotarget; 2015 Dec 29; 6(42):44289-305. PubMed ID: 26517239
    [Abstract] [Full Text] [Related]

  • 18. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
    Middleton FK, Patterson MJ, Elstob CJ, Fordham S, Herriott A, Wade MA, McCormick A, Edmondson R, May FE, Allan JM, Pollard JR, Curtin NJ.
    Oncotarget; 2015 Oct 20; 6(32):32396-409. PubMed ID: 26486089
    [Abstract] [Full Text] [Related]

  • 19. Role of Smac in determining the chemotherapeutic response of esophageal squamous cell carcinoma.
    Xu Y, Zhou L, Huang J, Liu F, Yu J, Zhan Q, Zhang L, Zhao X.
    Clin Cancer Res; 2011 Aug 15; 17(16):5412-22. PubMed ID: 21676925
    [Abstract] [Full Text] [Related]

  • 20. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.
    Hall AB, Newsome D, Wang Y, Boucher DM, Eustace B, Gu Y, Hare B, Johnson MA, Milton S, Murphy CE, Takemoto D, Tolman C, Wood M, Charlton P, Charrier JD, Furey B, Golec J, Reaper PM, Pollard JR.
    Oncotarget; 2014 Jul 30; 5(14):5674-85. PubMed ID: 25010037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.